Quidel Co. (NASDAQ:QDEL) SVP Robert Joseph Bujarski sold 110,704 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $39.78, for a total transaction of $4,403,805.12. Following the completion of the transaction, the senior vice president now directly owns 79,797 shares of the company’s stock, valued at approximately $3,174,324.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Quidel Co. (QDEL) opened at $40.00 on Monday. Quidel Co. has a fifty-two week low of $18.25 and a fifty-two week high of $45.55. The company has a debt-to-equity ratio of 0.70, a current ratio of 6.28 and a quick ratio of 5.68.

Quidel (NASDAQ:QDEL) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.21). The business had revenue of $50.89 million during the quarter, compared to the consensus estimate of $50.47 million. Quidel had a negative net margin of 2.33% and a negative return on equity of 2.36%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.10 EPS. equities analysts expect that Quidel Co. will post 0.6 EPS for the current fiscal year.

A number of research firms have recently commented on QDEL. Piper Jaffray Companies reissued a “buy” rating and issued a $50.00 target price on shares of Quidel in a report on Friday, November 3rd. Canaccord Genuity reissued a “buy” rating and issued a $48.00 target price on shares of Quidel in a report on Wednesday, October 25th. Barclays reissued a “buy” rating and issued a $45.00 target price (up previously from $39.00) on shares of Quidel in a report on Tuesday, September 19th. Zacks Investment Research cut shares of Quidel from a “hold” rating to a “strong sell” rating in a report on Tuesday, December 12th. Finally, BidaskClub raised shares of Quidel from a “sell” rating to a “hold” rating in a report on Saturday, December 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $48.80.

Hedge funds and other institutional investors have recently modified their holdings of the stock. TIAA CREF Investment Management LLC raised its holdings in Quidel by 1.1% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 99,227 shares of the company’s stock valued at $2,693,000 after buying an additional 1,062 shares during the last quarter. SG Americas Securities LLC raised its holdings in Quidel by 8.1% in the 2nd quarter. SG Americas Securities LLC now owns 38,347 shares of the company’s stock valued at $1,041,000 after buying an additional 2,871 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Quidel by 45.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 174,788 shares of the company’s stock valued at $4,744,000 after buying an additional 54,206 shares during the last quarter. Swiss National Bank raised its holdings in Quidel by 4.2% in the 3rd quarter. Swiss National Bank now owns 47,200 shares of the company’s stock valued at $2,070,000 after buying an additional 1,900 shares during the last quarter. Finally, Harvest Management LLC bought a new position in Quidel in the 3rd quarter valued at approximately $702,000. Institutional investors and hedge funds own 92.67% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/18/insider-selling-quidel-co-qdel-svp-sells-4403805-12-in-stock.html.

About Quidel

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Stock Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related stocks with our FREE daily email newsletter.